It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.
Recommended CitationDing, Qian; Zhang, Zugui; Liu, Hong; Nie, Huang; Berguson, Mark; Goldhammer, Jordan E.; Young, Nilas; Boyd, Douglas; Morris, Rohinton; and Sun, Jianzhong, "Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery." (2019). Department of Anesthesiology Faculty Papers. Paper 52.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.